香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因依賴該等內容而引致之 任何損失承擔任何責任。 承董事會命 東瑞製葯(控股)有限公司 主席 李其玲 香港，二零二五年八月十一日 於本公告日期，本公司董事會包括兩名執行董事李其玲女士及熊融禮先生；兩名非執行董事梁 康民先生及胡碩先生；以及三名獨立非執行董事勞同聲先生、EDE, Ronald Hao Xi先生及林明儀 女士。 * 僅供識別 DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED 東瑞製葯（控股）有限公司* （於開曼群島註冊成立的有限公司） （股份代號：2348） 董事會召開日期 東瑞製葯（控股）有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於二零二五年八月二十二日（星期五）舉行董事會會議，藉以（其中包括）考慮及批准 本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績及其刊發，以及考 慮派付中期股息（如有）。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02348 | 說明 | 東瑞製葯(控股)有限公司 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 HKD | | | 0.05 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 HKD | | | 0.05 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 II. ...

李其玲女士 (主席) 熊融禮先生 非執行董事 梁康民先生 胡碩先生 DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED 東瑞製葯（控股）有限公司* （於開曼群島註冊成立的有限公司） （股份代號：2348） 董事名單及其角色和職能 東瑞製葯(控股)有限公司董事會（「董事會」）成員載列如下: 執行董事 | 董事 | | 董事委員會 | | | --- | --- | --- | --- | | | 審核委員會 | 薪酬委員會 | 提名委員會 | | 李其玲 | | M | C | | 勞同聲 | C | M | M | | EDE, Ronald Hao Xi | M | C | M | | 林明儀 | M | M | M | 附註： C 有關委員會的主席 M 有關委員會的成員 香港，二零二五年八月一日 * 以供識別之用 獨立非執行董事 勞同聲先生 EDE, Ronald Hao Xi先生 林明儀女士 董事會轄下設立3個委員會。下表提供董事會成員在該等委員會中所擔任的職位。 ...

智通财经APP讯，东瑞制药(02348)发布公告，胡硕先生已获委任为公司非执行董事，自2025年8月1日起 生效。 ...

Core Viewpoint - Dongrui Pharmaceutical (02348) announced the appointment of Mr. Hu Shuo as a non-executive director, effective from August 1, 2025 [1] Company Summary - The appointment of Mr. Hu Shuo is a strategic move for Dongrui Pharmaceutical, indicating potential changes in governance and direction [1]

Group 1 - The core point of the article is the appointment of Hu Shuo as a non-executive director of Dongrui Pharmaceutical, effective from August 1, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責 ， 對其準 確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED 東瑞製葯(控股)有限公司* (於開曼群島註冊成立的有限公司) (股份代號: 2348) 委任非執行董事 根據董事會作出一切合理查詢後深知和盡悉及胡先生的確認，有關胡先生的委任，除上述 披露外，概無其他根據上市規則第 13.51(2)條第(h)至 13.51(2)條第(v)段規定須作出披露的資 料，亦無其他就委任胡先生一事須提請本公司證券持有人注意的事項。 本公告乃由東瑞製葯(控股)有限公司（「本公司」，連同其附屬公司統稱「本集團」）根 據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.51(2)條作出。 本公司董事會（「董事會」）欣然宣佈，胡碩先生（「胡先生」）已獲委任為本公司非執 行董事，自二零二五年八月一日起生效。 胡碩先生（曾用名:胡春雲），49歲，於貴州大學獲得工商管理碩士學位。胡先生現任上 海建信 ...

Summary of Key Points Core Viewpoint - As of July 14, a total of 138 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders including Green Heart Group Holdings, OK Blockchain, and Pearl River Steel Pipe [1]. Group 1: Top Performers - Green Heart Group Holdings (02999) achieved a closing price of 0.013 with a peak of 0.017, marking a 70.00% increase [1]. - OK Blockchain (01499) closed at 0.680, reaching a high of 0.690, reflecting a 48.39% rise [1]. - Pearl River Steel Pipe (01938) had a closing price of 0.335 and a peak of 0.340, resulting in a 33.33% increase [1]. Group 2: Other Notable Stocks - Weishi Jiajie (00856) saw a 32.01% increase, closing at 8.870 with a high of 11.300 [1]. - Cloud Intelligence (09678) reached a high of 520.000, closing at 510.000, which is a 20.99% increase [1]. - China Chengtong Development Group (00217) closed at 0.165 with a peak of 0.166, marking a 14.48% rise [1]. Group 3: Additional Stocks with Significant Increases - Sihuan Pharmaceutical (00460) closed at 1.380, reaching a high of 1.430, which is a 14.40% increase [1]. - Taited Pharmaceutical (03880) had a closing price of 36.950 and a peak of 37.400, reflecting a 13.85% rise [1]. - Beihai Kangcheng-B (01228) closed at 0.850 with a high of 0.960, resulting in a 12.94% increase [1].

Financial Performance - For the year ended December 31, 2024, the Group recorded revenue of approximately RMB1,060,309,000, representing a decrease of 7.9% compared to 2023[11]. - Profit attributable to owners of the parent was approximately RMB564,940,000, an increase of 73.3% compared to 2023[11]. - The profit included a net gain of RMB277,627,000 from the disposal of a 35% equity interest in AD Pharmaceuticals Co., Ltd.[12]. - Excluding non-recurring profits, the operating profit attributable to owners of the parent amounted to approximately RMB201,717,000, a decrease of 19.3% compared to 2023[12]. - The decrease in operating profit was mainly due to reduced sales of the "An" series products impacted by national centralized procurement[12]. - High production costs and inventory provision of RMB43,880,000 were recorded, compared to RMB10,936,000 in 2023[12]. - Losses from the bulk medicine and intermediate segment amounted to RMB60,975,000, compared to a loss of RMB32,692,000 in 2023[12]. - Total sales revenue declined by 7.9% compared to the same period in 2023, constrained by pricing pressures despite an increase in sales volume[28]. - The segment profit from the finished drugs segment was approximately RMB425,211,000, a decrease of RMB62,066,000 compared to RMB487,277,000 in 2023, mainly due to centralized procurement impacts[86]. - Gross profit was approximately RMB577,628,000, a decrease of RMB63,891,000 or 10.0%, with a gross profit margin of 54.5%, down 1.2 percentage points from the previous year[78]. Dividends - The Board recommends a final dividend of HK$0.048 per share for the year ended December 31, 2024, totaling approximately HK$72,091,000, a decrease from HK$97,516,000 in 2023[16]. - A special dividend of HK$0.032 per share is proposed, totaling approximately HK$48,061,000, subject to shareholder approval at the 2025 AGM[17]. - The total annual dividend distribution will be HK$0.095 per share, representing an 18.8% year-on-year increase from HK$0.080 in 2023[18]. - The annual dividend payout ratio is approximately 23.5%, slightly below the company's policy of at least 25% due to a one-time book gain of approximately RMB366,919,000 in 2024[18]. Market Challenges and Strategies - The Group's financial results reflect challenges in both domestic and overseas markets due to regulatory changes and operational adjustments[12]. - Future strategies may focus on improving production efficiency and expanding market presence to mitigate the impact of centralized procurement[12]. - The Group's sales volume for certain products decreased due to unsuccessful bids in national centralized procurement, while other categories like Atorvastatin Calcium Tablets and Entecavir Dispersible Tablets saw growth[28]. - The Group plans to increase R&D investment focusing on chronic diseases, antiviral, and antimicrobial fields, while also exploring anti-aging and nutritional health domains[36]. - The Group aims to enhance production efficiency through smart manufacturing and lean production to optimize cost structures[36]. - The Group will expand market channels by leveraging e-commerce platforms and exploring international markets to increase product coverage[36]. Research and Development - Approximately 60% of the ongoing R&D projects are self-developed, with a new PhD appointed as the head of the R&D team to optimize project management and enhance efficiency[31]. - The Suzhou Dawnrays Advanced Technology Research Institute has about 60% of its products under development as self-developed projects, focusing on generics and innovative drugs[29]. - The Group's R&D platform, Suzhou Dongrui Advanced Technology Research Institute, will continue to optimize talent structure and enhance technical capabilities, with a focus on increasing the proportion of independent R&D[59]. - The Group plans to increase R&D investment to diversify its product pipeline and aims to launch new products annually to drive future growth[56]. Production and Sales - The Group achieved a 22.5% increase in the production volume of intermediates and bulk medicines compared to 2023, and a 49.3% increase in the production volume of cephalosporin powder for injection[41]. - The sales volume of "Xianshu" (Cefoperazone Sodium and Sulbactam Sodium for Injection: (1:1)) increased by 21.3%, and the sales amount increased by 42.9% compared to the same period in 2023[44]. - The bulk medicine base in Suzhou obtained commercial production qualification, with primary products achieving commercial sales, enhancing the Group's market share in intermediates and bulk medicines[55]. - The sales volume of the antibiotic injection products has shown a steady recovery, with key products winning bids in national centralized procurement[54]. Governance and Compliance - The Board of Directors is composed of a balanced mix of executive and independent non-executive directors, ensuring strong governance and independent judgment[138][140]. - The Company has complied with the Corporate Governance Code, with the exception of two independent directors who could not attend the annual general meeting due to other commitments[135][136]. - The Company has mechanisms to ensure independent views from directors are conveyed to enhance decision-making[141]. - The governance framework is reviewed annually by the Board to ensure its effectiveness[141]. - The Company ensures that all Directors are properly briefed on issues arising at board meetings[167]. Financial Position and Cash Flow - The Group's cash and bank balances were approximately RMB1,158,261,000 as of December 31, 2024, an increase from RMB905,826,000 in the previous year[98]. - Net cash inflows from operating activities were approximately RMB220,200,000, down from RMB338,400,000 in 2023[98]. - The Group recorded net cash inflows from investing activities of approximately RMB205,170,000, compared to net cash outflows of RMB387,573,000 in the previous year[98]. - The Group's interest-bearing bank and other borrowings decreased to RMB29,864,000 as of December 31, 2024, from RMB120,060,000 in 2023, resulting in a debt ratio of 0.7% compared to 3.3% in the previous year[102]. Employee and Operational Management - As of December 31, 2024, the Group employed approximately 1,183 employees, an increase from 1,143 in 2023, with total remuneration of approximately RMB 230,667,000, up from RMB 211,780,000 in 2023, primarily due to staff increase and salary adjustments[120][123]. - The management is responsible for supplying the Board with monthly updates and adequate information for informed decision-making[166]. - Directors have independent access to management for further inquiries if needed[166]. Risk Management - The Group's risk management framework includes identifying significant risks, developing measures to mitigate them, and monitoring their effectiveness[180]. - The internal audit department continuously reviews major operational and financial controls, reporting directly to the Chairman of the Board and the Audit Committee[183]. - The Group has integrated its risk management systems into core operating practices, with business units assessing potential risks to achieve their objectives[182].

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 1,060,309, a decrease of 7.9% compared to RMB 1,151,145 in 2023[2] - Gross profit for the same period was RMB 577,628, down 10.0% from RMB 641,519, resulting in a gross margin of 54.5%, a decline of 1.2 percentage points[2] - Profit before tax increased by 53.8% to RMB 636,949 from RMB 414,057 in the previous year[3] - Net profit for the year was RMB 562,762, representing a 74.4% increase from RMB 322,667 in 2023[3] - Basic earnings per share rose by 72.7% to RMB 0.3754 from RMB 0.2174[3] - The company reported a total comprehensive income of RMB 577,777 for the year, compared to RMB 326,292 in 2023[4] - The company reported a loss from an associate company of RMB 3,696 thousand for the year ended December 31, 2024, compared to a loss of RMB 40,933 thousand in 2023[18] - The total income tax expense for 2024 was RMB 74,187,000, compared to RMB 91,390,000 in 2023, reflecting a reduction of approximately 19%[30] - The operating profit, excluding non-recurring gains, was RMB 201,717,000, a decline of 19.3% from RMB 249,954,000 in 2023[45] - The net profit attributable to the company's owners for the year was approximately RMB 564,940,000, an increase of RMB 238,940,000 or 73.3% from RMB 326,000,000 in 2023[76] Dividends - The company proposed a final dividend of HKD 0.048, a decrease of 26.2% from HKD 0.065 in the previous year, while the total proposed dividend for the year increased by 18.8% to HKD 0.095[2] - The company plans to distribute a final dividend of HKD 0.048 per share for 2024, down from HKD 0.065 in 2023, while introducing a special dividend of HKD 0.032 per share[35] - The board proposed a final dividend of HKD 0.048 per share for the year ending December 31, 2024, totaling approximately HKD 72,091,000, a decrease from HKD 97,516,000 in 2023[46] - The total annual dividend will be HKD 0.095 per share, representing an 18.8% increase compared to HKD 0.080 per share in 2023, with a payout ratio of approximately 23.5%[47] - The final dividend and special dividend will be distributed to shareholders on June 12, 2025[99] Assets and Liabilities - Non-current assets increased to RMB 1,807,035 from RMB 1,902,463, with property, plant, and equipment rising to RMB 1,038,195 from RMB 758,907[5] - Current assets grew to RMB 2,202,241 from RMB 1,720,196, with cash and bank deposits increasing to RMB 1,158,261 from RMB 905,826[5] - Total assets as of December 31, 2024, were RMB 4,009,276 thousand, an increase from RMB 3,622,659 thousand in 2023[17] - Total liabilities decreased to RMB 682,608 thousand in 2024 from RMB 763,425 thousand in 2023, reflecting improved financial health[17] - The company's liabilities ratio was 0.7%, down from 3.3% in 2023, with interest-bearing bank loans totaling RMB 29,864,000[82] Sales and Revenue Breakdown - Total revenue for the year ended December 31, 2024, was RMB 1,060,309 thousand, a decrease of 7.9% from RMB 1,151,145 thousand in 2023[20] - Sales of pharmaceutical products accounted for RMB 1,058,297 thousand, while testing services contributed RMB 2,012 thousand in 2024[21] - The pharmaceutical segment reported a profit of RMB 425,211,000, while the intermediates and raw materials segment incurred a loss of RMB 60,975,000 for the year ended December 31, 2024[16] - The sales revenue for the anti-hypertension series reached RMB 334,252,000, down from RMB 424,186,000 in 2023, accounting for 31.5% of total sales[57] - The sales revenue for anti-lipid products increased to RMB 299,372,000, up from RMB 292,331,000 in 2023, representing 28.2% of total sales[58] - The sales revenue for antiviral products rose to RMB 141,241,000, compared to RMB 124,828,000 in 2023, making up 13.3% of total sales[59] - The overall sales of powder injections increased to RMB 108,846,000, up from RMB 76,196,000 in 2023, representing 10.3% of total sales[60] Research and Development - Research and development expenses for the year amounted to RMB 70,755,000, down from RMB 84,611,000 in 2023, indicating a decrease of about 16%[28] - Approximately 60% of the products under development are self-researched projects, with a focus on first generics and improved innovative drugs to invigorate the product line[52] - The company is enhancing its R&D capabilities and plans to maintain a steady release of new products each year, focusing on therapeutic areas including cardiovascular, anti-infective, and antiviral drugs[62] - The company has made significant advancements in product quality and efficacy consistency studies, with 35 varieties under research, of which 31 specifications have been approved[63] Operational Performance - The company’s management monitors operational performance by product category, facilitating informed resource allocation decisions[14] - The company recorded a significant inventory provision of RMB 43,880,000, compared to RMB 10,936,000 in 2023, due to high production costs and low sales volumes[45] - The company has maintained a rigorous credit monitoring system to manage credit risk, with no significant concentration of credit risk among customers[38] - The company is actively responding to market changes and increasing R&D investment, aiming to occupy a favorable position in the procurement market and explore untapped markets[49] Market and Industry Trends - The global pharmaceutical industry continues to advance despite geopolitical tensions and high interest rates, with China's healthcare reforms focusing on improving service efficiency and high-quality development[48] - The company anticipates ongoing challenges but aims to enhance R&D investment, improve production efficiency, and expand market channels to meet rising drug demand driven by an aging population[53] Investments and Future Plans - The company has sufficient financial resources to cover capital expenditures and plans to potentially use bank loans for future investments[93] - The company aims for significant growth by 2025 through optimized marketing strategies and expanding cooperation with chain pharmacies and exploring new business models[56] - New production facilities in Suzhou and Lanzhou have received production approvals, although initial low output has led to higher costs and losses in raw materials and intermediates[50]